This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of the clinical study was conducted on an intention to treat basis. The method of multiple imputation was used to deal with missing data. The primary clinical end point used in the current economic evaluation was the variation in health-related quality of life. This was estimated using the EuroQol (EQ-5D) instrument, a standardised generic tool comprising five health dimensions. The main clinical measure used in the primary trial was a composite measure of three elements: suicidal acts, inpatient psychiatric hospitalisations, and accident and emergency attendance. The authors did not discuss the baseline comparability of the study groups, but the randomised design of the study suggests that the two groups were not statistically different at baseline. In addition, differences in mean quality-adjusted life-years (QALYs) between the two groups at follow-up were adjusted for differences in baseline EQ-5D scores.
Effectiveness results
The mean EQ-5D scores in the TAU and CBT+TAU groups were: The mean odds ratio based on the composite measure for CBT+TAU over TAU alone was 0.70 (95% CI: 0.38 to 1.31; p=0.27). This showed that the two treatment arms were similarly effective.
A significant reduction in the number of suicidal acts was reported in favour of CBT (mean odds ratio -0.91, 95% CI: 1.67 to -0.17; p=0.02).
Clinical conclusions
The effectiveness analysis showed that, on average, health-related quality of life was slightly lower in the intervention group than in the control group. However, the difference was small and did not reach statistical significance. In general, the two treatments were similarly effective.
Measure of benefits used in the economic analysis
The summary benefit measure used was the number of QALYs. These were derived directly from the effectiveness analysis using EQ-5D values. An annual discount rate of 3.5% was used to assess the present values of future benefits.
